Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Topical Minoxidil 5%: What the Clinical Trials Show

By
Published Updated Last reviewed
10 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Drug / minoxidil 5% topical solution or foam
  • Condition / androgenetic alopecia (pattern hair loss)
  • Evidence type / randomized, mostly double-blind, placebo-controlled trials, 16 to 48 weeks
  • 5% versus 2% in men / superior on hair count and patient and investigator ratings [1]
  • 5% versus 2% in women / superior to 2% only on patient-rated benefit [2]
  • Regulatory status / topical minoxidil 2% and 5% products are available over the counter [3]
  • Main gap / short follow-up and high heterogeneity across studies [4]

What the randomized trials show

Men: 393 men aged 18 to 49 were randomized to 5% solution (n=157), 2% solution (n=158) or placebo (n=78) twice daily for 48 weeks. The 5% solution was significantly superior to both for nonvellus hair count and for patient and investigator ratings, with earlier response and more itching and local irritation [1].

Women: 381 women aged 18 to 49 were randomized to 5% (n=153), 2% (n=154) or placebo (n=74) twice daily for 48 weeks. The 5% solution was superior to placebo on all three primary measures, 2% beat placebo on two of the three, and 5% beat 2% only on patient-rated treatment benefit; itching, irritation and hypertrichosis were more frequent with 5% [2].

Foam: in 352 men, 5% foam raised hair counts versus placebo at 16 weeks (P < .0001); no efficacy data were collected past 16 weeks, only safety data to 52 weeks in 143 men [5]. In 113 women treated for 24 weeks, 5% foam once daily was noninferior to 2% solution twice daily, with less local intolerance (P = .046); participants were not blinded because the formulations differed [6].

Where the evidence is thin

A 2017 meta-analysis that included only randomized trials rated good or fair found minoxidil superior to placebo in three groups of trials: 5% in men, 2% in men and 2% in women (P < .00001 for each). It flagged high heterogeneity in most studies [4].

The randomized trials above followed participants for 16 to 48 weeks [1][2][5]. Long-term evidence for 5% is limited. In a separate 31-man study of 2% and 3% solutions, regrowth tended to peak at about 1 year and then decline slowly, and nonvellus hair stayed above baseline at 4.5 to 5 years [7].

Comparisons with oral minoxidil are small: a double-blind trial randomized 90 men to oral 5 mg daily or topical 5% twice daily for 24 weeks, 68 completed, and no statistically significant between-group difference was reported [8].

What the labeling says

The men's 5% solution label says to apply 1 mL with a dropper twice daily to the top of the scalp, for men only, not for frontal baldness or a receding hairline. It says results may occur at 2 months and that some men may need at least 4 months [9]. It lists heart disease in a before-use warning [9]. The women's 5% foam label says to apply half a capful once daily, with results at about 3 months and possibly up to 6 [10].

Frequently asked questions

How strong is the evidence for topical minoxidil 5%?
Randomized trials consistently favor it over placebo in men and women, but follow-up is 16 to 48 weeks and studies measured hair differently. A 2017 meta-analysis of good- or fair-quality randomized trials found minoxidil superior to placebo in men and women and flagged high heterogeneity [4].
What did the 48-week 5% versus 2% trials show?
In 393 men, 5% beat both 2% and placebo on hair count and on patient and investigator ratings [1]. In 381 women, 5% beat placebo on all three primary measures but beat 2% only on patient-rated benefit [2].
How does oral minoxidil compare with topical 5%?
A 2024 double-blind trial randomized 90 men to oral 5 mg daily or topical 5% twice daily for 24 weeks; 68 completed, and no statistically significant between-group difference was reported [8].

References

  1. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
  2. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
  3. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  4. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis
  5. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
  6. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.e2. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
  7. Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643-6. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil
  8. Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatol. 2024;160(6):600-605. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial
  9. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  10. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
Evidence overview for topical minoxidil: Topical Minoxidil 5%: What the Clinical Trials Show